EVERSANA, Innovacell Partner to Advance ICEF15 Cell Therapy
CHICAGO, July 30, 2026 EVERSANA has been selected by Innovacell Inc. as its exclusive U.S. commercialization partner to support...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CHICAGO, July 30, 2026 EVERSANA has been selected by Innovacell Inc. as its exclusive U.S. commercialization partner to support...
CRANFORD, N.J., March 31, 2026 Citius Oncology, Inc. has reported strong early momentum following the U.S. launch of its...
BOSTON, Feb. 2, 2026 — Red Nucleus, a global strategic partner to pharmaceutical and biotechnology companies, announced a definitive...
